Related Experiment Videos
Serum lipoprotein(a) concentrations are related to coronary disease progression without new myocardial infarction
A Tamura1, T Watanabe, Y Mikuriya
1Second Department of Internal Medicine, Oita Medical University, Japan.
Insights
High serum lipoprotein(a) is linked to coronary artery disease progression. Lowering lipoprotein(a) may prevent disease advancement in patients with existing coronary artery disease and elevated levels.
Area of Science:
- Cardiology
- Biochemistry
- Medical Research
Background:
- Coronary artery disease (CAD) is a leading cause of mortality worldwide.
- Lipoprotein(a) [Lp(a)] is an emerging risk factor for atherosclerotic cardiovascular disease.
- Understanding predictors of CAD progression is crucial for effective patient management.
Purpose of the Study:
- To investigate the association between serum lipoprotein(a) levels and the progression of coronary artery disease.
- To identify independent predictors of CAD progression in patients without new myocardial infarction.
Main Methods:
- Serial coronary angiography was performed on 85 patients with CAD at least two years apart.
- CAD progression was defined as a ≥15% increase in diameter stenosis, excluding vessels with prior angioplasty.
- Serum lipoprotein(a) and other risk factors were analyzed in relation to disease progression.
Main Results:
- Serum lipoprotein(a) was significantly associated with CAD progression (P = 0.0002 univariate; P = 0.003 multivariate).
- Other factors associated with progression included cigarette smoking and serum low-density lipoprotein.
- Serum high-density lipoprotein was also an independent predictor of progression (P = 0.03).
Conclusions:
- Elevated serum lipoprotein(a) is a significant predictor of coronary artery disease progression independent of other risk factors.
- Lipoprotein(a) lowering therapies may be a viable strategy to prevent CAD advancement in at-risk individuals.
- Further research into Lp(a) targeted treatments is warranted for CAD management.
Objective:
To examine the association between serum lipoprotein(a) and angiographically assessed coronary artery disease progression without new myocardial infarction.
Patients And Design:
85 patients with coronary artery disease who underwent serial angiography with an interval of at least two years were studied. Progression of coronary artery disease was defined as an increase in diameter stenosis of 15% or more. Vessels on which angioplasty had been performed were excluded from the analysis. The patients were classified into two groups: a progression group without new myocardial infarction (n = 48) and non-progression group (n = 37). Risk factors including lipoprotein(a) were evaluated to see how they were related to progression without myocardial infarction.
Results:
There were no differences between the two groups in the following factors: age, gender, the time interval between the angiographic studies, the distribution of the analysed coronary arteries, and history of well established coronary risk factors. Univariate analysis showed that serum lipoprotein(a) (P = 0.0002), cigarette smoking between the studies (P = 0.002), serum high density lipoprotein (P = 0.003), and serum low density lipoprotein (P = 0.01) were related to progression without myocardial infarction. Multivariate analysis selected two independent factors for progression without myocardial infarction: serum lipoprotein(a) (P = 0.003) and serum high density lipoprotein (P = 0.03).
Conclusions:
Serum lipoprotein(a) concentrations are closely related to the progression of coronary artery disease without new myocardial infarction. Lipoprotein(a) lowering treatment may be needed to prevent disease progression in patients with coronary artery disease and high serum lipoprotein(a).